
    
      This study is designed to retrospectively review the medical and chemotherapy records of 300
      patients with EGFR mutation positive adenocarcinoma NSCLC. Eligible patients are as follows:
      histologically or cytologically confirmed NSCLC, undergone EGFR-TKI retreatment sometime
      after the failure of the initial EGFR-TKI. After initial treatment, patients had been treated
      with chemotherapy and subsequently re-treated with EGFR-TKI will be identified. The target
      population will be derived from multicentre in Taiwan. The study aim is to evaluate clinical
      effect in re-administration of EGFR-TKI using retrospectively collected data from these
      eligible patients to provide valuable information.
    
  